300 results found.

Breast Cancer, or Neoplasm Metastasis Clinical Trial using Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion

Prostate Cancer Clinical Trial using Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Metastatic Breast Cancer Clinical Trial using Cisplatin; Metronomic Cyclophosphamide

Centre Jean Perrin - Recruiting 18 years or older.
- .
Cisplatin; Metronomic Cyclophosphamide

Recurrent Melanoma, or Stage IV Melanoma Clinical Trial using NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma.
NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

Colorectal Cancer Metastatic Clinical Trial using TheraSphere

BTG International Inc. - Recruiting 18 years or older.
- A Phase III Clinical Trial Evaluating TheraSpherer in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.
TheraSphere

Metastatic Colorectal Cancer, Metastatic Gastric Cancer, Metastat Clinical Trial using CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers.
CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

Colorectal Cancer Metastatic Clinical Trial using AFLIBERCEPT AVE0005; FOLFIRI

Sanofi - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen.
AFLIBERCEPT AVE0005; FOLFIRI

Metastatic Breast Cancer Clinical Trial using Palbociclib; Fulvestrant; Placebo

Pfizer - Recruiting 18 years or older.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex?) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.
Palbociclib; Fulvestrant; Placebo

Colorectal Cancer Clinical Trial using panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Northwestern University - Recruiting 18 years or older.
- A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer.
panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Metastatic Melanoma, or Skin Cancer Clinical Trial using Cyclophosphamide; Fludarabine; Young TIL

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma.
Cyclophosphamide; Fludarabine; Young TIL

Prostate Cancer Clinical Trial using Best Systemic Therapy (BST); Best Systemic Therapy (BST) + Surgery or Radiation Therapy; Questionnaires; Phone Call/Email

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized, Phase II Trial of Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer (PC).
Best Systemic Therapy (BST); Best Systemic Therapy (BST) + Surgery or Radiation Therapy; Questionnaires; Phone Call/Email

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
BI 853520

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Non-Small Cell Lung Cancer Clinical Trial using Denosumab; Zometa

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer.
Denosumab; Zometa

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours.
BI 853520

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Japan Breast Cancer Research Group - Recruiting 20 years to 75 years.
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-.
Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Glioblastoma, or Recurrent Metastatic Cancer to the Brain Clinical Trial using ExAblate 4000

InSightec - Recruiting 18 years to 70 years.
- A Feasibility Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Lesions.
ExAblate 4000

Carcinoma, or Lymphoma Clinical Trial using rh IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers.
rh IL-15

HER2 Positive Metastatic Breast Cancers Clinical Trial using ONT-380; Capecitabine; Trastuzumab

Oncothyreon Inc. - Recruiting 18 years or older.
- A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer.
ONT-380; Capecitabine; Trastuzumab

Prostate Cancer, or Metastatic (Spread to Other Areas of the Body Clinical Trial using BKM120

Duke University - Recruiting 18 years or older.
- Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.
BKM120

Glioma, or Metastatic Brain Cancer Clinical Trial using ExAblate Transcranial System

InSightec - Recruiting 18 years to 75 years.
- A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors.
ExAblate Transcranial System

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Colorectal Cancer Clinical Trial using bevacizumab; FOLFIRI regimen; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer.
bevacizumab; FOLFIRI regimen; mFOLFOX6

Non-Small Cell Lung Cancer Clinical Trial using onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Genentech - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease.
onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Endometrial Cancer Clinical Trial using AEZS-108 / zoptarelin doxorubicin; doxorubicin

AEterna Zentaris - Recruiting 18 years or older.
- Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer..
AEZS-108 / zoptarelin doxorubicin; doxorubicin

Breast Cancer Clinical Trial using GDC-0941; placebo; fulvestrant; GDC-0980

Genentech - Recruiting 18 years or older.
- A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy.
GDC-0941; placebo; fulvestrant; GDC-0980

Breast Cancer Clinical Trial using GDC-0941; Placebo; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer.
GDC-0941; Placebo; paclitaxel

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
MPDL3280A

Breast Cancer Clinical Trial

Genentech - Recruiting 18 years or older.
- An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study))..

Head and Neck Cancer Clinical Trial using MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Colorectal Neoplasms Clinical Trial using Regorafenib (BAY73- 4506)

Bayer - Recruiting 18 years or older.
- An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy.
Regorafenib (BAY73- 4506)

Breast Cancer Clinical Trial using GDC-0032; Docetaxel; Paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
GDC-0032; Docetaxel; Paclitaxel

Gastric Cancer Clinical Trial using GDC-0068; Placebo; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
GDC-0068; Placebo; mFOLFOX6

Metastatic Breast Cancer Clinical Trial using PF-05280014; Paclitaxel; Herceptin®

Pfizer - Recruiting 18 years or older.
- A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast Cancer.
PF-05280014; Paclitaxel; Herceptin®

Metastatic Breast Cancer Clinical Trial using Anakinra plus Standard of Care

Baylor Research Institute - Recruiting 18 years to 80 years.
- Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients.
Anakinra plus Standard of Care

HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junc Clinical Trial using MM-111; Paclitaxel; Trastuzumab

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.
MM-111; Paclitaxel; Trastuzumab

Metastatic Colorectal Cancer Clinical Trial using Metastases resection; Bevacizumab; 5 FU (5Fluorouracile); Oxaliplatine; Irinotecan

Cliniques universitaires Saint-Luc- Université Catholique de Louvain - Recruiting 18 years or older.
- Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI.
Metastases resection; Bevacizumab; 5 FU (5Fluorouracile); Oxaliplatine; Irinotecan

Epithelial Cancer Clinical Trial using Lapatinib; Radiation therapy

Virginia Commonwealth University - Recruiting 18 years or older.
- A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease.
Lapatinib; Radiation therapy

Breast Cancer Clinical Trial using Paclitaxel; BKM120 matching placebo; BKM120

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation..
Paclitaxel; BKM120 matching placebo; BKM120

Metastatic Advanced Gastric Cancer Clinical Trial using Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Yonsei University - Recruiting 20 years or older.
- .
Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Advanced Cancer, Metastatic Cancer, Lymphoma, Metastatic Breast C Clinical Trial using LY3023414; Midazolam; Letrozole

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer.
LY3023414; Midazolam; Letrozole

Metastatic Colorectal Cancer Clinical Trial using Metastases Resection; 5-Fluorouracile; leucovorin L; Oxaliplatin; Irinotecan; Cetuximab

Cliniques universitaires Saint-Luc- Université Catholique de Louvain - Recruiting 18 years or older.
- Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors.
Metastases Resection; 5-Fluorouracile; leucovorin L; Oxaliplatin; Irinotecan; Cetuximab

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY.
MPDL3280A; docetaxel

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
MPDL3280A

Solid Tumors, Melanoma, or Metastatic Colorectal Cancer Clinical Trial using CEP-32496

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2.
CEP-32496

Metastatic GPNMB Over-expressing Triple Negative Breast Cancer Clinical Trial using CDX-011; Capecitabine

Celldex Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study).
CDX-011; Capecitabine

Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Recep Clinical Trial using nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Metastatic Breast Cancer Clinical Trial using Mammaglobin-A DNA vaccine

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients With Metastatic Disease.
Mammaglobin-A DNA vaccine

Metastatic Colorectal Cancer Clinical Trial using FOLFOXIRI + Cetuximab; FOLFOXIRI

Sun Yat-sen University - Recruiting 18 years to 75 years.
- A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver.
FOLFOXIRI + Cetuximab; FOLFOXIRI

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Metastatic Epidural Spinal Cord Compression Clinical Trial using Stereotactic Radiosurgery (SSRS)

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC).
Stereotactic Radiosurgery (SSRS)

Ocular Melanoma Clinical Trial using STA-9090

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma.
STA-9090

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, or Me Clinical Trial using Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT.
Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Cancer Metastatic to the Liver, Hepatocellular Carcinoma That is Clinical Trial using PV-10 (10% rose bengal disodium)

Provectus Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.
PV-10 (10% rose bengal disodium)

Differentiated Thyroid Cancer Clinical Trial using vandetanib; placebo

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy..
vandetanib; placebo

Melanoma Clinical Trial using WDVAX

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients.
WDVAX

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584

Neoplasms, Pancreas Clinical Trial using cancer stem cell vaccine

Fuda Cancer Hospital, Guangzhou - Recruiting 18 years to 75 years.
- Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas.
cancer stem cell vaccine

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors..
PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Metastatic Breast Cancer Clinical Trial using TDM1; Lapatinib; Abraxane

The Methodist Hospital System - Recruiting 18 years or older.
- Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients.
TDM1; Lapatinib; Abraxane

Gastric Cancer Clinical Trial using pertuzumab [Perjeta]; placebo; trastuzumab [Herceptin]; cisplatin; capecitabine; 5-fluorouracil

Hoffmann-La Roche - Recruiting 18 years or older.
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER.
pertuzumab [Perjeta]; placebo; trastuzumab [Herceptin]; cisplatin; capecitabine; 5-fluorouracil

Breast Cancer Clinical Trial using pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer..
pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Gastric Cancer Clinical Trial using trastuzumab emtansine; taxane

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction.
trastuzumab emtansine; taxane

Gastric Cancer Clinical Trial using Onartuzumab; Placebo; mFOLFOX6

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic Her2-Negative, Met-Positive Gastroesophageal Cancer (MetGastric).
Onartuzumab; Placebo; mFOLFOX6

Breast Cancer Clinical Trial using trastuzumab emtansine

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
trastuzumab emtansine

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Randomized, Multicenter Phase III Study in Patients With HER2-positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab.
trastuzumab [Herceptin]

Breast Cancer Clinical Trial using Kadcyla (trastuzumab emtansine)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment..
Kadcyla (trastuzumab emtansine)

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cance Clinical Trial using AUY922; BYL719

Novartis - Recruiting 18 years or older.
- A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
AUY922; BYL719

Head and Neck Cancer, or Squamous Cell Carcinoma of the Head and Clinical Trial using Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck.
Cisplatin; Docetaxel; Erlotinib; Placebo; Carboplatin

Advanced Cancers Clinical Trial using Oxaliplatin; Capecitabine; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.
Oxaliplatin; Capecitabine; Bevacizumab

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Met Clinical Trial using L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

Philogen S.p.A. - Recruiting 18 years to 70 years.
- Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy, Clinical Trial using Intermittent dosing of AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS).
Intermittent dosing of AZD5363

Metastatic Breast Cancer Clinical Trial using Fulvestrant; Goserelin; Anastrozole

Hospital Affiliated to Military Medical Science, Beijing - Recruiting 18 years to 60 years.
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer.
Fulvestrant; Goserelin; Anastrozole

Solid Tumors, or Metastatic Disease Clinical Trial using Histological biopsy procedure

UMC Utrecht - Recruiting 18 years or older.
- Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection).
Histological biopsy procedure

Metastatic Breast Cancer Clinical Trial using Docetaxel

Centro Universitario contra el Cáncer - Recruiting 21 years to 85 years.
- Docetaxel in Patients With Metastatic Breast Cancer Who Have Been Heavily Pretreated, Including Prior Treatment With Paclitaxel or Docetaxel..
Docetaxel

Hormone Receptor Positive Breast Cancer Clinical Trial using faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy..
faslodex 500mg; arimidex 1mg; faslodex dummy; arimidex dummy

Non-small Cell Lung Cancer Metastatic Clinical Trial using Ramucirumab; Placebo; Docetaxel

Eli Lilly and Company - Recruiting 20 years or older.
- A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.
Ramucirumab; Placebo; Docetaxel

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

FGFR Inhibition, Pharmacokinetics, Biomarkers, or ER+ Breast Canc Clinical Trial using AZD4547; Exemestane; Placebo; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW).
AZD4547; Exemestane; Placebo; Fulvestrant

Colorectal Cancer Clinical Trial using pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles

VU University Medical Center - Recruiting 18 years or older.
- Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET.
pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles

Prostate Cancer Clinical Trial using TAK-700; Bicalutamide

Southwest Oncology Group - Recruiting 18 years or older.
- A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer.
TAK-700; Bicalutamide

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using eribulin mesylate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.
eribulin mesylate; laboratory biomarker analysis; pharmacological study

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, or Stage Clinical Trial using counseling intervention; questionnaire administration; quality-of-life assessment

Stanford University - Recruiting N/A or older.
- Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers.
counseling intervention; questionnaire administration; quality-of-life assessment

Breast Cancer Clinical Trial using Lapatinib; Herceptin

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer.
Lapatinib; Herceptin

Multi-organ Metastatic Colorectal Cancer Clinical Trial using XELOX regimen according to standard procedures; FOLFOX regimen according to standard procedures; Surgery; radiofrequency ablation (RFA); transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE); stereotactic body radiation therapy (SBRT); Bevacizumab; tumor biopsy

VU University Medical Center - Recruiting 18 years or older.
- A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone..
XELOX regimen according to standard procedures; FOLFOX regimen according to standard procedures; Surgery; radiofrequency ablation (RFA); transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE); stereotactic body radiation therapy (SBRT); Bevacizumab; tumor biopsy

Metastatic Pancreatic Adenocarcinoma Clinical Trial using Ipilimumab; Vaccine; FOLFIRINOX

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer.
Ipilimumab; Vaccine; FOLFIRINOX

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Non-small Cell Lung Cancer Metastatic Clinical Trial using carboplatin; paclitaxel; ABP 215; bevacizumab

Amgen - Recruiting 18 years to 80 years.
- A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer.
carboplatin; paclitaxel; ABP 215; bevacizumab

Advanced Metastatic Breast Cancer Clinical Trial using AZD2014; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
AZD2014; Fulvestrant

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Metastatic Melanoma, or Skin Cancer Clinical Trial using Cyclophosphamide; Fludarabine; Tumor Infiltrating Lymphocytes; IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma.
Cyclophosphamide; Fludarabine; Tumor Infiltrating Lymphocytes; IL-15

Metastatic Cancer, Metastatic Melanoma, Renal Cancer, Colorectal Clinical Trial using Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes.
Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

Metastatic Melanoma, Metastatic Renal Cell Cancer, or Metastatic Clinical Trial using therapeutic autologous lymphocytes; aldesleukin; cyclophosphaide; fludarabine phosphate

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes.
therapeutic autologous lymphocytes; aldesleukin; cyclophosphaide; fludarabine phosphate

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of The Combination of Vismodegib and Sirolimus.
vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Metastatic Melanoma, or Skin Cancer Clinical Trial using Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI).
Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation

Metastatic Cancer, Pancreatic Cancer, Mesothelioma, Ovarian Cance Clinical Trial using Fludarabine; Cycolphosphamide; Aldesleukin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes.
Fludarabine; Cycolphosphamide; Aldesleukin

Breast Cancer, Breast Neoplasm, Breast Tumor, or Cancer of the Br Clinical Trial using Proton Radiotherapy

Proton Collaborative Group - Recruiting 18 years or older.
- Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Women With Stage III,Loco-Regional, Non-Metastatic Breast Cancer.
Proton Radiotherapy

Metastatic Renal Cell Cancer Clinical Trial using Everolimus

VU University Medical Center - Recruiting 18 years or older.
- Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer..
Everolimus

Prostatic Neoplasms Clinical Trial using Cabozantinib; Docetaxel; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
Cabozantinib; Docetaxel; Prednisone

Metastatic Cancers Other Than Melanoma That Express ESO Antigen, Clinical Trial using Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes.
Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

Local Advanced or Metastatic Postmenopausal Breast Cancer Clinical Trial

AstraZeneca - Recruiting N/A or older.
- LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer.

Prostate Cancer Metastatic Clinical Trial using CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Sanofi - Recruiting 18 years or older.
- Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy.
CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Reolysin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer.
Paclitaxel; Reolysin

Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, or Peri Clinical Trial using carboplatin; cisplatin; paclitaxel; quality-of-life assessment

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.
carboplatin; cisplatin; paclitaxel; quality-of-life assessment

Breast Neoplasms, or Breast Cancer Clinical Trial using Taxane; Taxotere; Abraxane; Ixabepilone

The Methodist Hospital System - Recruiting 18 years or older.
- Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy..
Taxane; Taxotere; Abraxane; Ixabepilone

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673; Physician's-Choice

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease.
BMN 673; Physician's-Choice

Non Small Cell Lung Cancer Clinical Trial using Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy..
Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

Prostate Cancer, Metastatic Prostate Cancer, or Castration-resist Clinical Trial

Astellas Pharma Inc - Recruiting N/A or older.
- A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis.

Metastatic Breast Cancer With Intracranial Metastases Clinical Trial using cabazitaxel; lapatinib

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases.
cabazitaxel; lapatinib

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study).

Gastric Cancer Clinical Trial using trastuzumab [Herceptin]; capecitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- .
trastuzumab [Herceptin]; capecitabine; cisplatin

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational Study of Avastin Plus 5-FU Based Chemotherapy as First Line Treatment for Chinese Patients With Metastatic Colorectal Cancer..

Breast Cancer Clinical Trial using Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer.
Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- STEAM (SEQUENTIAL TRIPLET AND AVASTIN MAINTENANCE): FOLFOXIRI/BEVACIZUMAB REGIMENS (CONCURRENT AND SEQUENTIAL) VS. FOLFOX/BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL CANCER.
bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Non-Small Cell Lunch Cancer Clinical Trial using BKM120; placebo; Carboplatin; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology.
BKM120; placebo; Carboplatin; Paclitaxel

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using veliparib; mitomycin C; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair.
veliparib; mitomycin C; laboratory biomarker analysis

Metastatic Breast Cancer Clinical Trial using eribulin mesylate; Trastuzumab

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy.
eribulin mesylate; Trastuzumab

Malignant Solid Tumour, or Gastroesophageal Cancer Clinical Trial using Tivantinib; FOLFOX

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II).
Tivantinib; FOLFOX

Head and Neck Cancer Clinical Trial using everolimus; laboratory biomarker analysis

Yonsei University - Recruiting 18 years or older.
- An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer.
everolimus; laboratory biomarker analysis

Melanoma Clinical Trial using Vemurafenib; IL-2; Interferon Alpha-2b

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Systemic Therapy of Metastatic Melanoma With Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor.
Vemurafenib; IL-2; Interferon Alpha-2b

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer Clinical Trial using GVAX Pancreas Vaccine; CRS-207; gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib; cyclophosphamide

Aduro BioTech, Inc. - Recruiting 18 years or older.
- A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma.
GVAX Pancreas Vaccine; CRS-207; gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib; cyclophosphamide

Neoplasms, Breast Clinical Trial using lapatinib; trastuzumab; Aromatase inhibitor

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies.
lapatinib; trastuzumab; Aromatase inhibitor

Breast Cancer Metastatic Clinical Trial using PF-03084014; Docetaxel

Pfizer - Recruiting 18 years or older.
- Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer.
PF-03084014; Docetaxel

Cancer Clinical Trial using Dabrafenib; Trametinib

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Dabrafenib; Trametinib

Renal Cell Carcinoma Clinical Trial using Arterial Spin Labeling Magnetic Resonance Imaging

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma.
Arterial Spin Labeling Magnetic Resonance Imaging

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinet Clinical Trial using AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies..
AZD5363

Breast Neoplasms Clinical Trial using Neratinib

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer.
Neratinib

Clear Cell Renal Cell Carcinoma, or Stage IV Renal Cell Cancer Clinical Trial using entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma.
entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

Prostatic Neoplams, Prostate Cancer, Neoplasm, Prostate, or Neopl Clinical Trial using AMG 386; Abiraterone; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer.
AMG 386; Abiraterone; Prednisone

Castrate Resistent Prostate Cancer Clinical Trial using BPX-201 vaccine plus AP1903

Bellicum Pharmaceuticals - Recruiting 18 years or older.
- A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC).
BPX-201 vaccine plus AP1903

Melanoma Clinical Trial using GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)

GlaxoSmithKline - Recruiting 18 years or older.
- Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma.
GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)

Metastatic Castration-resistant Prostate Cancer, or Metastatic Br Clinical Trial using Abiraterone acetate

Janssen Research & Development, LLC - Recruiting N/A or older.
- A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Abiraterone acetate

Prostate Cancer Metastatic Clinical Trial using PROSTVAC-V; PROSTVAC-F; GM-CSF; GM-CSF Placebo; Placebo

Bavarian Nordic, Inc. - Recruiting 18 years or older.
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
PROSTVAC-V; PROSTVAC-F; GM-CSF; GM-CSF Placebo; Placebo

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation.
BMN 673

Bladder Cancer, or Urothelial Carcinoma Clinical Trial using OGX-427; Docetaxel

Hoosier Oncology Group - Recruiting 18 years or older.
- The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160.
OGX-427; Docetaxel

Colon Cancer Clinical Trial using chemotherapy and GI-4000; GI-4000

Georgetown University - Recruiting 18 years or older.
- A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI in Patients With Newly Diagnosed Ras Mutant Positive Metastatic Colorectal Cancer or Patients With Ras Mutant Positive Colorectal Cancer Who Have Just Completed a First Line Therapy With an Oxaliplatin or Irinotecan Plus Fluoropyrimidine and Bevacizumab Containing Regimen.
chemotherapy and GI-4000; GI-4000

Metastatic Pancreatic Cancer Clinical Trial using Veliparib and 5-FU and Oxaliplatin and Leucovorin

Georgetown University - Recruiting 18 years or older.
- A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer.
Veliparib and 5-FU and Oxaliplatin and Leucovorin

Pancreatic Cancer Clinical Trial using Gem-OX; Gem-5FU; Gem-Tax; Modified FOLFOX-6; Ox-Tax; FOLFIRI; Tax-Iri

Georgetown University - Recruiting 18 years or older.
- A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer.
Gem-OX; Gem-5FU; Gem-Tax; Modified FOLFOX-6; Ox-Tax; FOLFIRI; Tax-Iri

Stage IV Gastric Cancer Clinical Trial using Paclitaxel

Daehwa Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxolr in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum.
Paclitaxel

Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, o Clinical Trial using OGX-427; Abiraterone Acetate; Prednisone

Hoosier Oncology Group - Recruiting 18 years or older.
- The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159.
OGX-427; Abiraterone Acetate; Prednisone

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Gastric Cancer Clinical Trial using Rilotumumab; Placebo

Amgen - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Rilotumumab; Placebo

Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Clinical Trial using sipuleucel-T

Dendreon - Recruiting 18 years or older.
- An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer.
sipuleucel-T

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using eribulin mesylate; laboratory biomarker analysis

University of Washington - Recruiting 18 years or older.
- Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC).
eribulin mesylate; laboratory biomarker analysis

Colorectal Cancers Clinical Trial using RENCA macrobeads

The Rogosin Institute - Recruiting 18 years or older.
- A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma.
RENCA macrobeads

Metastatic Colorectal Cancer Clinical Trial using Blood analysis by EPISPOT and Cellsearch

University Hospital, Montpellier - Recruiting 18 years or older.
- Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment.
Blood analysis by EPISPOT and Cellsearch

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Solid Tumors, Cancer, or NSCLC Clinical Trial using cabozantinib capsules; cabozantinib tablets

Exelixis - Recruiting 20 years or older.
- Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
cabozantinib capsules; cabozantinib tablets

Breast Neoplasm, or Metastasis Clinical Trial using Eribulina

Medica Scientia Innovation Research - Recruiting 18 years or older.
- A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.
Eribulina

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

Leukemia, Lymphoid Malignancies, or Metastatic Malignant Neoplasm Clinical Trial using Intrathecal Rituximab

M.D. Anderson Cancer Center - Recruiting 3 years or older.
- Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System.
Intrathecal Rituximab

Metastatic Breast Cancer Clinical Trial using fresolimumab (GC1008); Radiation Therapy

New York University School of Medicine - Recruiting 18 years or older.
- Fresolimumab and Radiotherapy in Metastatic Breast Cancer.
fresolimumab (GC1008); Radiation Therapy

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Prostate Cancer Clinical Trial using DSTP3086S

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer.
DSTP3086S

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Desmo Clinical Trial using vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.
vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

Colorectal Neoplasm Clinical Trial using Regorafenib (Stivarga, BAY 73-4506)

Bayer - Recruiting 18 years or older.
- RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy.
Regorafenib (Stivarga, BAY 73-4506)

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

Breast Cancer, HER-2 Positive Breast Cancer, or Triple Negative B Clinical Trial using ganetespib

Synta Pharmaceuticals Corp. - Recruiting 18 years or older.
- An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
ganetespib

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer.
bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using tivozanib; pharmacological study; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma.
tivozanib; pharmacological study; laboratory biomarker analysis

Prostate Cancer Clinical Trial using PSMA ADC

Progenics Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer.
PSMA ADC

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study of Avastinr First-line in Metastatic Colorectal Cancer (Koralle).

Liver Cancer, or Metastatic Cancer Clinical Trial using capecitabine; yttrium Y 90 glass microspheres

Northwestern University - Recruiting 18 years or older.
- Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.
capecitabine; yttrium Y 90 glass microspheres

Metastatic Colorectal Cancer Clinical Trial using Xeloda

Samsung Medical Center - Recruiting 18 years or older.
- A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer.
Xeloda

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

City of Hope Medical Center - Recruiting 65 years or older.
- Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Metastatic Breast Cancer.
paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

Metastatic Colorectal Cancer Clinical Trial using MEK162; Panitumumab

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer.
MEK162; Panitumumab

Breast Cancer Clinical Trial using palliative surgery; therapeutic conventional surgery; palliative radiation therapy; radiation therapy

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer.
palliative surgery; therapeutic conventional surgery; palliative radiation therapy; radiation therapy

Breast Cancer Clinical Trial using TPI 287; Dexamethasone; Benadryl; Ranitidine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain.
TPI 287; Dexamethasone; Benadryl; Ranitidine

Prostate Neoplasms, or Prostate Cancer Clinical Trial using Cohort 4; Cohort 3; Cohort 2; Cohort 1

Cougar Biotechnology, Inc. - Recruiting 18 years or older.
- A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Cohort 4; Cohort 3; Cohort 2; Cohort 1

Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistan Clinical Trial using sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer.
sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

Gastrointestinal Cancer Clinical Trial using Panitumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater.
Panitumumab

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer.
Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Metastatic Colorectal Cancer Clinical Trial using Cetuximab; Capecitabine

Swiss Group for Clinical Cancer Research - Recruiting 70 years or older.
- Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial.
Cetuximab; Capecitabine

Breast Cancer Clinical Trial using BKM120

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer.
BKM120

Asian Chemo-na‹ve Patients With Metastatic Castrate-resistant Pro Clinical Trial using Tasquinimod; Placebo

Ipsen - Recruiting 20 years or older.
- A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Na‹ve Patients With Metastatic Castrate-Resistant Prostate Cancer.
Tasquinimod; Placebo

Recurrent Breast Cancer, or Metastatic Breast Cancer Clinical Trial using Ruxolitinib; Paclitaxel

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer.
Ruxolitinib; Paclitaxel

Effects of Chemotherapy, or Stage IVC Nasopharyngeal Carcinoma Clinical Trial using Recombinant Human Endostatin plus gemcitabine and cisplatin; Gemcitabine and cisplatin

Zhejiang Cancer Hospital - Recruiting 18 years to 65 years.
- A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage ? Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma.
Recombinant Human Endostatin plus gemcitabine and cisplatin; Gemcitabine and cisplatin

Breast Neoplasms Clinical Trial using Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting.
Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Advanced or Metastatic Breast Cancer,, or ER+ve Advanced or Metas Clinical Trial using AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

AstraZeneca - Recruiting 18 years or older.
- A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status..
AZD5363 when combined with weekly paclitaxel.; AZD5363when combined with weekly paclitaxel.; A placebo in combination with weekly paclitaxel.

Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Bod Clinical Trial using ipilimumab; yttrium Y 90 glass microspheres; laboratory biomarker analysis

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver.
ipilimumab; yttrium Y 90 glass microspheres; laboratory biomarker analysis

Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Pro Clinical Trial using laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

University of Southern California - Recruiting 18 years or older.
- A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.
laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

Metastatic Prostate Cancer Clinical Trial using cabacitaxel

Tampere University Hospital - Recruiting 18 years or older.
- Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen.
cabacitaxel

Neoplasms Clinical Trial using bevacizumab plus docetaxel

Tampere University Hospital - Recruiting 18 years or older.
- Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.
bevacizumab plus docetaxel

Breast Cancer Clinical Trial using MAB HER 2 (HERCEPTIN)

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity.
MAB HER 2 (HERCEPTIN)

Metastatic Ovarian Cancer Clinical Trial using Experimental arm

Centre Val d'Aurelle - Paul Lamarque - Recruiting 18 years or older.
- Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring.
Experimental arm

Metastatic Hepatocellular Carcinoma, or Advanced Liver Cancer Clinical Trial using Ascorbic Acid + Sorafenib; Sorafenib alone

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma.
Ascorbic Acid + Sorafenib; Sorafenib alone

Stage IV Pancreatic Cancer Clinical Trial using Ascorbic Acid

Thomas Jefferson University - Recruiting 18 years or older.
- Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer.
Ascorbic Acid

Breast Neoplasm Clinical Trial

Medica Scientia Innovation Research - Recruiting 18 years or older.
- Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib.

Prostate Cancer Clinical Trial using Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer.
Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

Colorectal Cancer Clinical Trial using Folfox plus Bevacizumab and reolysin; Folfox plus Bevacizumab

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer..
Folfox plus Bevacizumab and reolysin; Folfox plus Bevacizumab

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Colorectal Cancer Clinical Trial using GS-6624; FOLFIRI; Placebo to match GS-6624

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen..
GS-6624; FOLFIRI; Placebo to match GS-6624

Prostate Cancer Clinical Trial using CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Sanofi - Recruiting 18 years or older.
- A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context..
CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER.

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum.

Non-small Cell Lung Cancer Clinical Trial using Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Leo W. Jenkins Cancer Center - Recruiting 18 years or older.
- A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent.
Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 75 years or older.
- Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin r Regimen for Metastatic Colorectal Cancer..

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase IIIb, Open-label Study of Erlotinib (Tarcevar) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE).
erlotinib [Tarceva]

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 70 years or older.
- Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years.

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer.
trastuzumab [Herceptin]; paclitaxel; docetaxel

Pancreatic Cancer Clinical Trial using TH-302; Nab-paclitaxel; Gemcitabine

EMD Serono - Recruiting 18 years or older.
- An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma.
TH-302; Nab-paclitaxel; Gemcitabine

Melanoma Clinical Trial using ABI-007; Ipilimumab; Phone Call

M.D. Anderson Cancer Center - Recruiting 12 years to 70 years.
- Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma.
ABI-007; Ipilimumab; Phone Call

Breast Cancer Clinical Trial using Pegylated liposomal doxorubicin

University of Arizona - Recruiting 18 years or older.
- A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin.
Pegylated liposomal doxorubicin

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Colorectal Cancer Clinical Trial using Cetuximab; Neratinib

National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older.
- A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With 'Quadruple Wild-Type' (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab.
Cetuximab; Neratinib

Melanoma Clinical Trial using Ipilimumab; Temozolomide; Cisplatin; Interferon Alfa-2b; Interleukin-2

M.D. Anderson Cancer Center - Recruiting 18 years to 65 years.
- IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma.
Ipilimumab; Temozolomide; Cisplatin; Interferon Alfa-2b; Interleukin-2

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using MLN8237 and Erlotinib

Fox Chase Cancer Center - Recruiting 18 years or older.
- A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer.
MLN8237 and Erlotinib

Melanoma Clinical Trial using GSK2118436; GSK1120212

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor.
GSK2118436; GSK1120212

Metastatic Castration-resistant Prostate Cancer Clinical Trial using Taxotere; Jevtana

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer.
Taxotere; Jevtana

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

Metastatic Pancreatic Cancer, or Pancreatic Cancer Clinical Trial using Folfirinox

Yale University - Recruiting 18 years or older.
- Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer.
Folfirinox

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Metastatic Transitional Cell Carcinoma of the Urothelium Clinical Trial using Buparlisib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium.
Buparlisib

Cancer Clinical Trial using Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors.
Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

Metastatic Colorectal Cancer Clinical Trial using aflibercept + FOLFIRI

CR-CSSS Champlain-Charles-Le Moyne - Recruiting 18 years or older.
- A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
aflibercept + FOLFIRI

Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Clinical Trial using nilotinib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor.
nilotinib

Advanced or Metastatic Solid Tumors, or Advanced or Metastatic Br Clinical Trial using Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

University of Utah - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

Primary Breast Cancer, or Recurrent/Metastatic Breast Cancer Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Breast Cancer Proteomics and Molecular Heterogeneity.

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of t Clinical Trial using Ipilimumab; Best Supportive care (BSC)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer.
Ipilimumab; Best Supportive care (BSC)

Prostate Cancer Clinical Trial using Orteronel; Bicalutamide

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration..
Orteronel; Bicalutamide

Colorectal Cancer Metastatic Clinical Trial using aflibercept AVE0005

Sanofi - Recruiting 20 years or older.
- A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen.
aflibercept AVE0005

Brain Cancer Clinical Trial

University of Utah - Recruiting 18 years or older.
- Assessment of Primary and Metastatic Brain Tumor Hypoxia With 18F-Fluoromisonidazole, [18F]Fluoro-2-deoxy-D-glucose (FDG) and [15O]Water (H215O).

Colorectal Cancer Metastatic, Liver Metastases, or KRAS Wild Type Clinical Trial using FOLFOX6; Bevacizumab; Panitumumab; Surgery

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 75 years.
- Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS Colorectal Cancer.
FOLFOX6; Bevacizumab; Panitumumab; Surgery

Non-Small Cell Lung Cancer Clinical Trial using Custirsen + Docetaxel; Docetaxel

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer.
Custirsen + Docetaxel; Docetaxel

Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Clinical Trial using ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

City of Hope Medical Center - Recruiting 18 years or older.
- A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer.
ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

Her2 Positive Metastatic Breast Cancer Clinical Trial using non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes.
non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

Breast Cancer Clinical Trial using Eribulin; Carboplatin

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer.
Eribulin; Carboplatin

Metastatic Colorectal Cancer, Colon Cancer, or Rectal Cancer Clinical Trial using IMMU-130

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer..
IMMU-130

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

HER2-positive Breast Cancer, Recurrent Breast Cancer, or Stage IV Clinical Trial using pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer.
pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Prostate Cancer Clinical Trial using PET/CT; PET/MRI

New York University School of Medicine - Recruiting 18 years or older.
- Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients.
PET/CT; PET/MRI

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Hoffmann-La Roche - Recruiting 18 years or older.
- An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT].
bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Metastatic Prostate Cancer Clinical Trial using sipuleucel-T; enzalutamide

Dendreon - Recruiting 18 years or older.
- A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer.
sipuleucel-T; enzalutamide

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study).

Pancreatic Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label Study of Erlotinib (Tarcevar) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
erlotinib [Tarceva]

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Metastatic Solid Tumors Clinical Trial using MLN1117

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease.
MLN1117

Metastatic Castration Sensitive Prostate Cancer Clinical Trial using Degarelix; Ipilimumab; Radical Prostatectomy

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study Combining Ipilimumab and Degarelix With Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer.
Degarelix; Ipilimumab; Radical Prostatectomy

Lung Cancer, or Metastatic Cancer Clinical Trial using computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy.
computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Bre Clinical Trial using entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Multicenter Study of First-line Avastinr (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer.

Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uv Clinical Trial using tumor specimens

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Clinical and Histopathologic Characteristics of BAP1 Mutations.
tumor specimens

Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Clinical Trial using pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors.
pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

Esophageal Cancer, or Gastric Cancer Clinical Trial using Regorafenib; 5-Fluorouracil; Leucovorin; Oxaliplatin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer.
Regorafenib; 5-Fluorouracil; Leucovorin; Oxaliplatin

Thyroid Neoplasms Clinical Trial using Ponatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer.
Ponatinib

Pancreatic Cancer Clinical Trial using LY2495655; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy.
LY2495655; Placebo

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib.
LY2875358; Erlotinib

Prostate Cancer Clinical Trial using Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Medivation, Inc. - Recruiting 18 years or older.
- A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Na‹ve Metastatic Castration-Resistant Prostate Cancer.
Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Neoplasms, Neoplasm Metastasis, or Lymphoma Clinical Trial using LY3039478

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer.
LY3039478

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Gastric Cancer Clinical Trial using Ramucirumab

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients.
Ramucirumab

Advanced, Metastatic Breast Cancer Clinical Trial using LEE011; Letrozole; Letrozole Placebo

Novartis - Recruiting N/A or older.
- A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
LEE011; Letrozole; Letrozole Placebo

Tumors Metastatic to Brain, or Unspecified Adult Solid Tumor Clinical Trial using stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Dose Escalation for Larger Brain Metastases: Phase I/II Study.
stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, or Metastatic Clinical Trial using Cabazitaxel-XRP6258

University of Alabama at Birmingham - Recruiting 19 years or older.
- Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.
Cabazitaxel-XRP6258

Tumors Metastatic to Brain Clinical Trial using radiosurgery; therapeutic conventional surgery; quality-of-life assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study.
radiosurgery; therapeutic conventional surgery; quality-of-life assessment

Colorectal Cancer Metastatic Clinical Trial using Regorafenib (BAY 73-4506); FOLFIRI; Placebo

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer.
Regorafenib (BAY 73-4506); FOLFIRI; Placebo

Non-small Cell Lung Cancer Metastatic Clinical Trial using Erlotinib

National Guard Health Affairs - Recruiting 18 years or older.
- Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME).
Erlotinib

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status.
6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status.
6,8-bis(benzylthio)octanoic acid

Pancreatic Cancer, or Colorectal Cancer Clinical Trial using Cancer macrobead placement in abdominal cavity

The Rogosin Institute - Recruiting 18 years or older.
- An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma.
Cancer macrobead placement in abdominal cavity

Recurrent Squamous Cell Carcinoma of the Nasopharynx, or Stage IV Clinical Trial using Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Non-small Cell Lung Cancer Metastatic Clinical Trial using cisplatin, docetaxel

National Guard Health Affairs - Recruiting 18 years or older.
- A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer.
cisplatin, docetaxel

Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Clinical Trial using ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies.
ipilimumab; laboratory biomarker analysis

Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, or S Clinical Trial using wild-type reovirus; carboplatin; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysinr) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer.
wild-type reovirus; carboplatin; paclitaxel

Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers.
6,8-bis(benzylthio)octanoic acid

Colorectal Cancer Metastatic Clinical Trial using AFLIBERCEPT AVE0005; OXALIPLATIN; CAPECITABINE

Sanofi - Recruiting 18 years or older.
- A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient.
AFLIBERCEPT AVE0005; OXALIPLATIN; CAPECITABINE

Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Ca Clinical Trial using Cisplatin; Gemcitabine; ALT-801

Altor Bioscience Corporation - Recruiting 18 years or older.
- A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.
Cisplatin; Gemcitabine; ALT-801

Prostate Cancer Clinical Trial using Flutamide; Sargramostim; recombinant fowlpox-prostate apecific antigen vaccine; recombinant vaccinia prostate specific antigen vaccine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer.
Flutamide; Sargramostim; recombinant fowlpox-prostate apecific antigen vaccine; recombinant vaccinia prostate specific antigen vaccine

Melanoma, Ovarian Cancer, Renal Cell Cancer, or Non-small Cell Lu Clinical Trial using IDC-G305

Immune Design - Recruiting 18 years to 80 years.
- A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer.
IDC-G305

Renal Cell Carcinoma Clinical Trial using BKM-120 Bevacizumab

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.
BKM-120 Bevacizumab

Gastric Cancer Clinical Trial using Cabazitaxel

Krankenhaus Nordwest - Recruiting 18 years or older.
- Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach.
Cabazitaxel

Metastatic Colorectal Cancer, or EGFR-Expressing Metastatic CRC Clinical Trial using Sorafenib (Bay 43-9006); cetuximab; proteomic profiling; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; pharmacological study; biopsy

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC).
Sorafenib (Bay 43-9006); cetuximab; proteomic profiling; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; pharmacological study; biopsy